Zacks.com on MSN1d
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded UseAstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...
The race bibs we wore always said, “I walk for Wilma Parnell,” my maternal grandmother, who died from breast cancer when my ...
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...
AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application ...
Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...
The sBLA is supported by results from the phase IIIDESTINY-Breast06 trial (NCT04494425), which showed that patients with HER2 ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...
Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that ...
Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback